India suspends import and manufacture of rosiglitazone and combinations
This article was originally published in Scrip
India has suspended the importation and manufacture of the diabetes drug, rosiglitazone, following recent international regulatory action against the original branded version, GlaxoSmithKline's Avandia, and other rosiglitazone-containing products in view of the molecule's link to cardiovascular safety issues.
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.